Michael Barbella, Managing Editor04.16.24
ENDRA Life Sciences Inc. has been issued three new patents on three continents—one in the United States, one in China, and one in Europe.
ENDRA’s intellectual property portfolio now includes 74 issued patents worldwide providing protection for its Thermo Acoustic Enhanced UltraSound (TAEUS) system that features thermoacoustic technology. The new patents protect innovations integral to the TAEUS system, ensuring maximum radiofrequency energy absorption, minimized signal noise and precise temperature monitoring during surgical procedures, and thermal ablation. With the ability to accurately monitor temperature changes during thermal therapies, clinicians can, for example, optimize treatment parameters to minimize damage to healthy tissue while effectively targeting cancerous cells, leading to better therapeutic outcomes and reduced side effects.
“We are proud of our growing patent estate. These newly issued patents reinforce ENDRA's commitment to advancing thermoacoustic systems, and expand the horizons for our TAEUS technology to address unmet clinical needs," ENDRA Chief Technology Officer Michael Thornton said. "We remain committed to fortifying our intellectual property to safeguard our technology in key global markets, deploying a portfolio that now encompasses 74 granted patents."
The issued patents include:
ENDRA’s intellectual property portfolio now includes 74 issued patents worldwide providing protection for its Thermo Acoustic Enhanced UltraSound (TAEUS) system that features thermoacoustic technology. The new patents protect innovations integral to the TAEUS system, ensuring maximum radiofrequency energy absorption, minimized signal noise and precise temperature monitoring during surgical procedures, and thermal ablation. With the ability to accurately monitor temperature changes during thermal therapies, clinicians can, for example, optimize treatment parameters to minimize damage to healthy tissue while effectively targeting cancerous cells, leading to better therapeutic outcomes and reduced side effects.
“We are proud of our growing patent estate. These newly issued patents reinforce ENDRA's commitment to advancing thermoacoustic systems, and expand the horizons for our TAEUS technology to address unmet clinical needs," ENDRA Chief Technology Officer Michael Thornton said. "We remain committed to fortifying our intellectual property to safeguard our technology in key global markets, deploying a portfolio that now encompasses 74 granted patents."
The issued patents include:
- U.S. Patent No. 11844650, “Thermoacoustic Measurement Probe,” protects a novel sleeve-type structural configuration for TAEUS that maximizes radiofrequency energy absorption and the corresponding thermoacoustic signal strength. The sleeve-type configuration also minimizes signal noise to provide a clearer thermoacoustic signal. Embodiments cited in the patent utilize a plurality of radiofrequency feeds that enable signal polarization and lead to a clearer thermoacoustic measurement.
- Chinese Patent No. ZL2021800757024, “Thermal Ablation System with Integrated Thermoacoustic Temperature Measurement,” relates to the TAEUS system determining temperature at a specific location in the human body. For example, the patent protects a system designed to monitor temperature during thermal ablation for overheating to avoid destroying healthy tissue and underheating to mitigate not destroying targeted cancerous tumor cells.
- European Patent No. EP3902490, “Method and System for Monitoring Tissue Temperature,” relates to a method with the TAEUS system for monitoring tissue temperature during surgical procedures, such as thermotherapy and cryotherapy.